Reinventing the Stethoscope and Cardiopulmonary Care

Why It Matters

Early, accurate detection of cardiovascular disease can cut preventable deaths and bring specialist‑level diagnostics into primary‑care settings, expanding access and improving outcomes.

Key Takeaways

• AI stethoscope detects heart failure 2.3× more than traditional auscultation.
• Atrial fibrillation identification rises 3.5× with Eko CORE 500.
• Over 400,000 clinicians worldwide already using Eko digital stethoscopes.
• FDA cleared for murmurs, AFib, low ejection fraction detection.
• Infineon PSoC 63 MCU powers low‑power, real‑time AI analysis.

Pulse Analysis

Cardiovascular disease remains the world’s leading cause of death, yet most diagnoses still occur after symptoms appear. Traditional auscultation relies on clinician skill and is vulnerable to ambient noise, limiting its sensitivity. By embedding AI algorithms directly into a handheld stethoscope, Eko Health transforms a centuries‑old tool into a predictive screening platform, enabling clinicians to flag subtle murmurs and rhythm disturbances that would otherwise go unnoticed.

The CORE 500’s performance in the TRICORDER study underscores its clinical value: primary‑care providers detected heart failure, atrial fibrillation, and ventricular disease at multiples of the rates achieved with standard stethoscopes. Real‑time analysis, cloud‑based storage, and Bluetooth connectivity streamline workflow, allowing instant sharing of recordings with cardiologists and facilitating tele‑consultations. As a result, practices can intervene earlier, potentially averting the estimated 200,000 preventable heart‑attack and stroke deaths each year in the United States.

Underpinning this breakthrough is Infineon’s PSoC 63 Bluetooth LE microcontroller and XENSIV MEMS microphones, which deliver high‑fidelity audio and low‑power processing within a device no larger than a traditional stethoscope. The combination of edge AI, secure data transmission, and long battery life positions the device for global deployment, from urban clinics to remote field hospitals. Analysts see a growing market for AI‑enhanced diagnostic tools, and Eko’s FDA clearances across multiple algorithms give it a competitive edge as health systems prioritize cost‑effective, scalable solutions for early disease detection.